[1] Liu R, Han C, Wu D, et al.Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis[J]. Biomed Res Int, 2015, 2015(10): 762-820. [2] Cheng L, Xiong Y, Qin CZ, et al.HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study[J]. Br J Dermatol, 2015, 173(2): 555-558. [3] Wu R, Cheng YJ, Zhu LL, et al.Impact of HLA-B*5801 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies[J]. Oncotarget, 2016, 7(49): 81870-81879. [4] Zhang X, Ma H, Hu C, et al.Detection of HLA-B*58:01 with TaqMan assay and its association with allopurinol-induced sCADR[J]. Clin Chem Lab Med, 2015, 53(3): 383-390. [5] Khanna D, Fitagerald JD, Khanna PP, et al.2012 american college of rheumatology guidelines for management of gout. part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia[J]. Arthritis Care Res (Hoboken), 2012, 64(10): 1431-1446. [6] Chinese society of endocrinology. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019)[J]. Chin J Endocrinol Metab(中华内分泌代谢杂志), 2020, 36(1): 1-13. [7] Hung SI, Chung WH, Liou LB, et al.HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol[J]. Proc Natl Acad Sci USA, 2005, 102(11): 4134-4139. [8] Jutkowitz E, Dubreuil M, Lu N, et al.The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States[J]. Semin Arthritis Rheum, 2017, 46(5): 594-600. [9] Deng ZY, Yang J, Yang WL.Detection of the HLA-B* 5801 allele in Han Chinese with allopurinol-induced severe drug eruption[J]. Diagn Ther J Dermatol-Venereol(皮肤性病诊疗学杂志), 2013, 20(6): 379-382. [10] Ng CY, Yeh YT, Wang CW, et al.Impact of the HLA-B(*)5801 allele and renal impairment on allopurinol-induced cutaneous adverse reactions[J]. J Invest Dermatol, 2016, 136(7): 1373-1381. [11] Wang CW, Dao RL, Chung WH.Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions[J]. Curr Opin Allergy Clin Immunol, 2016, 16(4): 339-345. [12] Wang CT.Risk analysis and measures of toxic epidermal necrosis caused by allopurinol[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(8): 485-487. |